Quarterly ResultAug 5, 2026, 04:11 PM
Black Diamond Q2 2026 Net Loss $9.91M; H1 Net Loss $18.94M
AI Summary
Black Diamond Therapeutics reported a net loss of $9.91 million for Q2 2026 and $18.94 million for the first half of 2026. This compares to net losses of $10.56 million and net income of $45.98 million for the respective periods in 2025, which included a $70.0 million upfront payment from the Servier Agreement. The company expects its current cash, cash equivalents, and investments to fund operations for at least the next 12 months and continues to evaluate strategic alternatives for its product candidates and seek additional funding.
Key Highlights
- Q2 2026 net loss was $9.91 million, compared to a net loss of $10.56 million in Q2 2025.
- H1 2026 net loss was $18.94 million, compared to net income of $45.98 million in H1 2025.
- Cash and cash equivalents totaled $19.19 million as of June 30, 2026.
- Total assets were $125.03 million as of June 30, 2026.
- Accumulated deficit reached $483.68 million as of June 30, 2026.
- Sold 4,490,853 common shares via ATM program for $24.5 million net proceeds.
- Received $70.0 million upfront payment from Servier Agreement in March 2025.
- Expects existing cash to fund operations for at least the next 12 months.
Price Impact
More from BDTX